Cargando…

Evolocumab enables rapid LDL-C reduction and inflammatory modulation during in-hospital stage of acute coronary syndrome: A pilot study on Chinese patients

BACKGROUND AND AIMS: Proprotein convertase subtilisin/kexin type 9 (PCSK9) has long been considered a key regulator in lipid metabolism. Its role as a potential player in immune response has recently earned much attention. However, the effects of evolocumab, an approved PCSK9 monoclonal antibody, on...

Descripción completa

Detalles Bibliográficos
Autores principales:	Ou, Ziwei, Yu, Zaixin, Liang, Benhui, Zhao, Lin, Li, Jianghua, Pang, Xinli, Liu, Qiyun, Xu, Cong, Dong, Shaohong, Sun, Xin, Li, Tangzhiming
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2022
Materias:	Cardiovascular Medicine
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9397913/ https://www.ncbi.nlm.nih.gov/pubmed/36017088 http://dx.doi.org/10.3389/fcvm.2022.939791

Ejemplares similares

Iron metabolism-related genes reveal predictive value of acute coronary syndrome
por: Xu, Cong, et al.
Publicado: (2022)

Novel lncRNA LNC_000113 Drives the Activation of Pulmonary Adventitial Fibroblasts through Modulating PTEN/Akt/FoxO1 Pathway
por: Luo, Hui, et al.
Publicado: (2023)

Long-term prognosis analysis of PARACHUTE device implantation in patients with ischemic heart failure: a single-center experience of Chinese patients
por: Li, Jianghua, et al.
Publicado: (2021)

Evolocumab lowers LDL-C safely and effectively when self-administered in the at-home setting
por: Dent, Ricardo, et al.
Publicado: (2016)

Diagnosis of rapidly progressed primary cardiac lymphoma in liver transplant recipient: A case report
por: Li, Jianghua, et al.
Publicado: (2022)

FRI097 A Case Of Evolocumab-induced Transaminitis Revealing A Gastrointestinal Melanoma
por: Nava Suarez, Corina, et al.
Publicado: (2023)

Cost‐Effectiveness of LDL‐C Lowering With Evolocumab in Patients With High Cardiovascular Risk in the United States
por: Gandra, Shravanthi R., et al.
Publicado: (2016)

Combination of Dichloroacetate and Atorvastatin Regulates Excessive Proliferation and Oxidative Stress in Pulmonary Arterial Hypertension Development via p38 Signaling
por: Li, Tangzhiming, et al.
Publicado: (2020)

A retrospective cohort study on the association between early coagulation disorder and short-term all-cause mortality of critically ill patients with congestive heart failure
por: Tang, Yiyang, et al.
Publicado: (2022)

Corrigendum: A retrospective cohort study on the association between early coagulation disorder and short-term all-cause mortality of critically ill patients with congestive heart failure
por: Tang, Yiyang, et al.
Publicado: (2022)

Methodology and results of cost-effectiveness of LDL-C lowering with evolocumab in patients with acute myocardial infarction in China
por: Wan, Yuansheng, et al.
Publicado: (2023)

Reduction of Vascular Inflammation, LDL-C, or Both for the Protection from Cardiovascular Events?
por: Reklou, Andromachi, et al.
Publicado: (2018)

Restoring mortality data in the FOURIER cardiovascular outcomes trial of evolocumab in patients with cardiovascular disease: a reanalysis based on regulatory data
por: Erviti, Juan, et al.
Publicado: (2022)

Effect of alirocumab and evolocumab on all-cause mortality and major cardiovascular events: A meta-analysis focusing on the number needed to treat
por: Wang, Hong-Fei, et al.
Publicado: (2022)

Case report: Echocardiographic diagnosis of double orifice mitral valve in an asymptomatic woman
por: Deng, Zixian, et al.
Publicado: (2023)

Clinical efficacy and safety of evolocumab for low-density lipoprotein cholesterol reduction
por: Henry, Courtney A, et al.
Publicado: (2016)

The Role of Fasting LDL-C Levels in Their Non-fasting Reduction in Patients With Coronary Heart Disease
por: Lin, Qiuzhen, et al.
Publicado: (2021)

Rapid disease progress in a PVOD patient carrying a novel EIF(2)AK(4) mutation: a case report
por: Zeng, Xiaofang, et al.
Publicado: (2020)

Effects of Evolocumab on Cardiovascular Events
por: Mikhail, Nasser
Publicado: (2017)

Painful and recurring injection site reaction to alirocumab and evolocumab in a young woman with familial hypercholesterolemia and effective therapeutic alternative based on inclisiran: a case report
por: Allevi, Massimiliano, et al.
Publicado: (2023)

Effects of evolocumab therapy and low LDL‐C levels on vitamin E and steroid hormones in Chinese and global patients with type 2 diabetes
por: Blom, Dirk J., et al.
Publicado: (2020)

Exploring the Efficacy of Alirocumab and Evolocumab in Reducing Low-Density Lipoprotein (LDL) Cholesterol Levels in Patients With Familial Hypercholesterolemia: A Systematic Review
por: Luthra, Gaurav, et al.
Publicado: (2022)

Retargeting the management of hypercholesterolemia – focus on evolocumab
por: Colletti, Alessandro, et al.
Publicado: (2016)

Retrograde recanalization of radial artery occlusion via the distal transradial artery: A single-center experience
por: Lin, Yaowang, et al.
Publicado: (2022)

Consistent LDL‐C response with evolocumab among patient subgroups in PROFICIO: A pooled analysis of 3146 patients from phase 3 studies
por: Stroes, Erik, et al.
Publicado: (2018)

Evolocumab is initiated in Central and Eastern Europe at Much Higher LDL-C Levels than Recommended in Guidelines: Results from the Observational HEYMANS Study
por: Blaha, V, et al.
Publicado: (2023)

Comparison of the Reductions in LDL-C and Non-HDL-C Induced by the Red Yeast Rice Extract Xuezhikang Between Fasting and Non-fasting States in Patients With Coronary Heart Disease
por: Zhu, Li-Yuan, et al.
Publicado: (2021)

Profile of evolocumab and its potential in the treatment of hyperlipidemia
por: Cicero, Arrigo FG, et al.
Publicado: (2015)

Efficacy of Evolocumab in Monogenic vs Polygenic Hypercholesterolemia
por: Lee, Timothy, et al.
Publicado: (2019)

Maculopapular Exanthema After the Second Dose of Evolocumab
por: Ghernautan, Victoria, et al.
Publicado: (2021)

Evolocumab loaded Bio-Liposomes for efficient atherosclerosis therapy
por: Li, Zhenxian, et al.
Publicado: (2023)

Eligibility for alirocumab or evolocumab treatment in 1090 hypercholesterolemic patients referred to a regional cholesterol treatment center with LDL cholesterol ≥70 mg/dL despite maximal-tolerated LDL-cholesterol-lowering therapy
por: Jetty, Vybhav, et al.
Publicado: (2017)

Very low LDL‐C levels may safely provide additional clinical cardiovascular benefit: the evidence to date
por: McCormack, Terry, et al.
Publicado: (2016)

Targets of statins intervention in LDL-C metabolism: Gut microbiota
por: Sun, ChangXin, et al.
Publicado: (2022)

Glycation of LDL: AGEs, impact on lipoprotein function, and involvement in atherosclerosis
por: Poznyak, Anastasia V., et al.
Publicado: (2023)

PCSK9 inhibition in the management of hyperlipidemia: focus on evolocumab
por: Blom, Dirk J, et al.
Publicado: (2016)

Influence of Renal Function on Evolocumab Exposure, Pharmacodynamics, and Safety
por: Lee, Edward, et al.
Publicado: (2019)

Atrial Fibrillation as a Possible Adverse Reaction to Evolocumab
por: Abdelmaseih, Ramy, et al.
Publicado: (2021)

PCSK9 Functions in Atherosclerosis Are Not Limited to Plasmatic LDL-Cholesterol Regulation
por: Luquero, Aureli, et al.
Publicado: (2021)

The accuracy of four formulas for LDL-C calculation at the fasting and postprandial states
por: Xu, Jin, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_k0ct1vmjds2mngb8inngii1dje